Valion Bio, Inc. Accrued Professional Fees, Current
Valion Bio, Inc. (VBIO) had Accrued Professional Fees, Current of $143.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Professional Fees, Current $143.00K.
- 2026-03-31: Accrued Professional Fees, Current $103.00K.
- 2025-12-31: Accrued Professional Fees, Current $24.00K.
- 2025-09-30: Accrued Professional Fees, Current $29.00K.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2026-06-30 | $143.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $103.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $24.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $29.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $96.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $122.00K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $39.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |